Mr. David Feifarek is a toxicologist in ToxStrategies’ Health Sciences Practice. He has seven years of experience in federal government and industry regulatory toxicology, performing novel research and developing quantitative risk assessments for consumer and professional personal care, air care, home cleaning, and biocidal products, while participating in corporate strategic development and sustainability initiatives. His background includes delivery of fit-for-purpose assessments of consumer cosmetics and drugs regulated by the US FDA, EU Cosmetic Products Regulation, and EU Biocidal Products Regulation. He is familiar with guidelines from the Scientific Committee on Consumer Safety (SCCS, European Commission), Cosmetic Ingredient Review (CIR) assessments, and FDA monographs.
Mr. Feifarek’s knowledge base includes a strategic understanding of the Globally Harmonized System of Classification and Labeling of Chemicals (GHS) and the EU Classification, Labelling, and Packaging (CLP) legislation, as well as product hazard labeling regulations in North America, Europe, and the Asia-Pacific and Australia-New Zealand regions. He has developed and implemented product safety claims (e.g., non-toxic, biodegradable, septic-safe), and he has in-depth working experience in screening for endocrine-disrupting properties of chemicals in accordance with EU REACH and Biocidal Product Regulation (BPR), as well as novel approach methodologies and priority data sources to screen for endocrine activity and adversity. His early work with USEPA contributed to the development and documentation of Adverse Outcome Pathways (AOPs) for estrogen, androgen, and steroidogenesis disruption. Mr. Feifarek’s work has been recognized by his employers on multiple occasions, including an award in 2021 for establishing the company as an industry leader in understanding endocrine disruptor toxicology, and a 2020 award for developing novel methods of predicting endocrine-disrupting potential in chemicals.